Bacteriophages, or phages, are viruses that only attack and kill bacteria. They are among the most common biological organisms capable of battling and destroying bacteria with multiple medication resistance. Phages can destroy the bacteria that cause an infection after all antibiotics have failed to treat it, enabling medical professionals to preserve a life. Bacteriophages are being researched as a potential new antibiotic. In this therapy, viruses are used to inject their genetic material into bacteria and develop by using the host system. Patients who have bacterial infections are treated or prevented using this phage therapy. Research in the fields of molecular biology and technology both heavily rely on bacteriophage therapy. These components increase the range of potential medication discovery.
Throughout the projection period, the rising prevalence of antibiotic-resistant infections (such as Salmonella typhi, Mycobacterium tuberculosis, and Pseudomonas aeruginosa) is anticipated to propel market growth and raise the number of fatalities. The market for bacteriophage therapy is anticipated to grow quickly in the coming years due to the existence of important industry players. In order to boost their pipelines of phage therapy candidates and to advance their research and development capabilities, market participants are putting more and more emphasis on inorganic expansion tactics like alliances and partnerships.
Over the projected period (2020-2030), the global Bacteriophage Therapy Market is anticipated to have a CAGR of 3.7%.
Major Players in the Bacteriophage Therapy Industry:
1. Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. was founded in 2005 and headquartered in California United States. It operates globally.. Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (collectively, "Innoviva"), a biotechnology company specializing in antibiotic-resistant and challenging-to-treat bacterial infections, announced in July 2023 that it had entered into a credit and security agreement with it.
2. Eliava Biopreparations Ltd.
Eliava Biopreparations Ltd. was founded in 2008 and headquartered in Georgia. It operates globally.
3. Pherecydes Pharma
Pherecydes Pharma was founded in 2006 and headquartered in Romainville, Ile-de-France, France. It operates in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced in June 2023 that it had submitted an application to the ANSM (the French National Agency for the Safety of Medicines) for the approval of a phase I clinical study in Staphylococcus aureus (S. aureus) infective endocarditis.
4. Intralytix, Inc.
Intralytix, Inc. is a privately owned biotech venture, was founded in 1998 and headquartered in Maryland, United States. It operates across the worldwide. At the University of Maryland School of Medicine (UMSOM) in Baltimore, Intralytix, Inc. declared the successful conclusion of its Phase 1 clinical trial in March 2023. The ShigActiveTM phage therapy product from Intralytix, which aims to prevent or minimize the severity of Shigella infections, will be tested in a clinical trial to determine its safety. The National Institute of Allergy and Infectious Diseases (NIAID) of the NIH is a contributor to the experiment's funding.
5. Phagelux, Inc.
Phagelux, Inc. was founded in 2013 and headquartered in Shanghai, China. It sell its products directly within China and partners with multinational companies for outside markets. In April 2020, Phagelux AgriHealth, Inc., a global agro biotechnology corporation focused on the research and commercialization of novel phage products and solutions, announced a slew of new agreements. OmniLytics, Inc., a wholly owned subsidiary of Phagelux AgriHealth, Inc., announced Ryan Benson, Director of US Sales and Marketing, that the company has signed an exclusive European sales, marketing, and product development deal with DCM for its AgriPhage biopesticide range.
6. Nextbiotics
Nextbiotics is a biotechnology platform that engineers viruses for good. It was founded in 2017 and headquartered in California, United States. It operates in.
7. InnoPhage, Ltd
InnoPhage, Ltd was founded in and headquartered in Portugal. It operates internationally.
8. Locus Biosciences, Inc.
Locus Biosciences, Inc. was founded in 2015 and headquartered in North Carolina, United States. It operates globally. The ELIMINATE study has started enrolling patients, and the first patient has been treated, according to Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology business creating a novel class of precision engineered bacteriophage medicines for a variety of bacterial disorders. To treat urinary tract infections (UTIs) brought on by Escherichia coli (E. coli) bacteria, lead candidate LBP-EC01, a CRISPR-enhanced bacteriophage (crPhage®) precision medicine, is being tested in the Phase 2/3 clinical study ELIMINATE.
9. TechnoPhage
TechnoPhage was founded in 2005 and headquartered in Lisbon, Portugal. It operates across the world. In December 2022, TechnoPhage will disclose the results of an innovative clinical experiment using a bacteriophage cocktail to treat diabetic foot infections.
10. Eligo Bioscience SA
Eligo Bioscience SA was founded in 2014 and headquartered in Paris, Ile-de-France, France. It operates in more than 10 countries.
*Definition: Small, virus-like creatures called bacteriophages infect bacteria. They consist of an RNA or DNA genome enclosed in a protein capsule.
